Stocks Health care RYTM
NASDAQ · Health careRhythm Pharmaceuticals, Inc. (RYTM)
Rhythm Pharmaceuticals, Inc. brought in $280.7M of revenue over the twelve months to September 30, 2026, up 61.0% from a year earlier. It posted a net loss of $193.8M. In fiscal 2025 capital spending exceeded operating cash flow by $116.6M. At September 30, 2026 it held $40M in cash against $102.7M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 3, 2026.
Key facts about Rhythm Pharmaceuticals, Inc.
- Net worth
- Rhythm Pharmaceuticals, Inc. has a market value (market cap) of $7.7B at the latest share price, and shareholders' equity of $88M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $189.8M (+45.8% year on year), with a net loss of $196.5M. Over the 12 months to September 30, 2026: revenue $280.7M, net loss $193.8M.
- Cash flow
- In fiscal 2025 operations used $115.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 3, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Rhythm Pharmaceuticals, Inc.'s next report is expected around January 8, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Rhythm Pharmaceuticals, Inc. does
Rhythm Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RYTM.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $189.8M | -$196.5M | -$3.11 | -$116.6M |
| 2024 | $130.1M | -$260.6M | -$4.34 | -$113.9M |
| 2023 | $77.4M | -$184.7M | -$3.20 | -$136.2M |
| 2022 | $23.6M | -$181.1M | -$3.47 | -$173.7M |
| 2021 | $3.2M | -$69.6M | -$1.40 | -$146.4M |
| 2020 | $0 | -$134M | -$3.04 | -$122.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where RYTM ranks in Health care
Latest SEC filings
What Rhythm Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 80% to $92.1M versus the same quarter last year; diluted EPS -$0.61 versus -$0.82.
- November 3, 2026
- October 13, 2026Passive stake (5% or more) SCHEDULE 13G
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 47% to $71.3M versus the same quarter last year; diluted EPS -$0.73 versus -$0.75.
- August 4, 2026
- June 25, 2026
- June 15, 2026
- May 29, 2026Additional proxy material DEFA14A
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 5, 2026
Insider trades
What the people running Rhythm Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $22.2M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 14, 2026 | Meeker David PPresident and CEO, Director | Exercised options | 50,000 | $302.5K |
| September 14, 2026 | Meeker David PPresident and CEO, Director | Soldpre-planned (10b5-1) | 6,439 | $655.1K |
| September 14, 2026 | Meeker David PPresident and CEO, Director | Soldpre-planned (10b5-1) | 30,746 | $3.1M |
| September 14, 2026 | Meeker David PPresident and CEO, Director | Soldpre-planned (10b5-1) | 8,698 | $899.6K |
| September 14, 2026 | Meeker David PPresident and CEO, Director | Soldpre-planned (10b5-1) | 1,817 | $190K |
| September 14, 2026 | Meeker David PPresident and CEO, Director | Soldpre-planned (10b5-1) | 2,300 | $241.9K |
| August 31, 2026 | Smith Hunter CChief Financial Officer | Exercised options | 57,187 | $1.5M |
| August 31, 2026 | Smith Hunter CChief Financial Officer | Soldpre-planned (10b5-1) | 23,072 | $2.4M |
Who owns RYTM
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| RA Capital Management, L.P.13G, passive with 3 related filers | 9.9% | February 17, 2026 |
| Baker Bros. Advisors LP13G, passive with 3 related filers | 8.9% | May 15, 2025 |
| The Goldman Sachs Group, Inc. ------------------------------------------------------------------------------13G, passive with 1 related filers | 6.4% | November 12, 2024 |
| Primecap Management Co13G, passive | 5.21% | February 12, 2026 |
| Perceptive Advisors LLC13G, passive with 3 related filers | 5.1% | May 15, 2026 |
| Vanguard Capital Management13G, passive | 5.02% | April 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 303 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| RA Capital Management, L.P. | 6,666,837 | 0 |
| BlackRock, Inc. | 6,156,902 | -80,249 |
| Baker Bros. Advisors LP | 5,604,483 | 0 |
| Primecap Management Co | 3,168,853 | -248,656 |
| Vanguard Portfolio Management LLC | 3,136,895 | +96,177 |
| Vanguard Capital Management LLC | 3,005,977 | +38,152 |
| Jpmorgan Chase & Co | 2,652,746 | +1,099,102 |
| Perceptive Advisors LLC | 2,586,295 | +212,500 |
| State Street Corp | 2,573,529 | +301,678 |
| Westfield Capital Management Co LP | 2,208,595 | +279,472 |
| Goldman Sachs Group Inc | 2,126,502 | +161,070 |
| Federated Hermes, Inc. | 1,785,716 | +499,413 |
| Polar Capital Holdings Plc | 1,663,632 | +48,046 |
| Geode Capital Management, LLC | 1,533,698 | +117,429 |
| Capital Research Global Investors | 1,532,303 | +416,843 |
| Citadel Advisors LLC | 1,263,652 | -154,967 |
| Checkpoint Capital L.P. | 1,186,000 | -41,200 |
| Siren, L.L.C. | 1,136,275 | +410,764 |
| Morgan Stanley | 1,112,240 | +408,262 |
| Fmr LLC | 1,025,840 | -663,831 |
Insiders
12 insiders reported holding 529,251 shares in total, about $59.4M at the last price.
| Holder | Shares |
|---|---|
| Meeker David PPresident and CEO, Director | 239,258 |
| Smith Hunter CChief Financial Officer | 114,024 |
| Mazabraud YannEVP, Head of International | 55,655 |
| Cramer Pamela J.Chief Human Resources Officer | 29,376 |
| Shulman JosephChief Technical Officer | 15,915 |
| Mathers Edward TDirector | 14,16814,168 held indirectly |
| Mcgirr David W JDirector | 11,712 |
| Good Jennifer LDirector | 11,712 |
| Jean ChristopheDirector | 11,712 |
| Arbuckle Stuart ADirector | 11,712 |
Questions about RYTM
What does Rhythm Pharmaceuticals, Inc. do?
Rhythm Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as RYTM. Its shares trade on NASDAQ under the ticker RYTM.
What is Rhythm Pharmaceuticals, Inc.'s net worth?
Rhythm Pharmaceuticals, Inc. has a market value (market cap) of $7.7B at the latest share price, and shareholders' equity of $88M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Rhythm Pharmaceuticals, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $193.8M on revenue of $280.7M.
How much revenue does Rhythm Pharmaceuticals, Inc. make?
Over the twelve months to September 30, 2026 Rhythm Pharmaceuticals, Inc. reported revenue of $280.7M. That is 61.0% more than a year earlier.
When did Rhythm Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 3, 2026. It covers the period to September 30, 2026.
When is Rhythm Pharmaceuticals, Inc.'s next earnings report?
Rhythm Pharmaceuticals, Inc.'s next report is expected around January 8, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare RYTM with
Follow RYTM
Get an email when Rhythm Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Rhythm Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.